European Journal of Clinical Microbiology & Infectious Diseases · 2019 · 100 citations · 30 references
Life SciencesInfectious DiseasesAntimicrobial ResistanceAntimicrobial Resistance EpidemiologyMedical MicrobiologyAntibiotic ResistanceAntimicrobial Susceptibility TestingBacterial EpidemiologyUrinary Tract InfectionsAntibiotic Resistance GenesAntibiotic Resistance ProfilingAntibiotic Resistance ScreeningAntibiotic Susceptibility Data AnalysisAntibiotic Susceptibility TestingAntimicrobial Resistance In Urinary Tract InfectionsEscherichia ColiEscherichia Coli Resistance
Recommendations of first choice antibiotic therapy need to be based on actual antibiotic susceptibility data. We determined the antibiotic susceptibility of E. coli in uncomplicated UTI among women and compared the results with 2004 and 2009. In 30 sentinel general practitioner practices of Nivel Primary Care database, urine samples were collected from women with symptoms of uncomplicated UTI. Patient characteristics, E. coli susceptibility, and ESBL production were analyzed. Six hundred eighty-nine urine samples were collected; E. coli was the most isolated uropathogen (83%). Antibiotic susceptibility was stable over time except for ciprofloxacin (96% in 2004, 97% in 2009, and 94% in 2014; P < 0.05). The susceptibility to co-amoxiclav was 88%, 87%, and 92% in 2004, 2009, and 2014, respectively. The prevalence of ESBL-producing E. coli increased from 0.1% in 2004 to 2.2% in 2014 (P < 0.05). Regional differences in antibiotic susceptibility for co-trimoxazole were found being the highest in the west (88%) and the lowest in the north (72%, P = 0.021). Ciprofloxacin susceptibility was related to antibiotic use in the past 3 months (97% no use versus 90% use, P = 0.002) and age > 70 years (P = 0.005). In 2014, prescription of fosfomycin increased compared to 2009 (14.3% versus 5.6%) at the expense of co-amoxiclav, co-trimoxazole, and fluoroquinolones (P < 0.05). The susceptibility percentages to most antimicrobial agents tested were stable over 10 years' period although the prevalence of E. coli and ESBLs significantly increased. Performance of a survey with regular intervals is warranted.
30
Maris S. Arcilla, Jarne M. van Hattem, Manon Haverkate et al. · The Lancet Infectious Diseases · 2016 · 461 citations · Full text
Gian Carlo Schito, Kurt G. Naber, Henry Botto et al. · International Journal of Antimicrobial Agents · 2009 · 416 citations · Full text
Inês Linhares, Teresa Raposo, António E. Rodrigues et al. · BMC Infectious Diseases · 2013 · 290 citations · Full text
Ann Versporten, Ganna Bolokhovets, Lilit Ghazaryan et al. · The Lancet Infectious Diseases · 2014 · 286 citations · Full text